2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.
Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.
According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.
The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
Related Content: